Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Biosci. 2012 Feb 27;2(1):6. doi: 10.1186/2045-3701-2-6.

BRCA1 tumor suppressor network: focusing on its tail.

Author information

  • 1Department of Genetics, The University of Texas M,D, Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1010, Houston, TX 77030, USA. bwang3@mdanderson.org.

Abstract

Germline mutations of the BRCA1 tumor suppressor gene are a major cause of familial breast and ovarian cancer. BRCA1 plays critical roles in the DNA damage response that regulates activities of multiple repair and checkpoint pathways for maintaining genome stability. The BRCT domains of BRCA1 constitute a phospho-peptide binding domain recognizing a phospho-SPxF motif (S, serine; P, proline; × varies; F, phenylalanine). The BRCT domains are frequently targeted by clinically important mutations and most of these mutations disrupt the binding surface of the BRCT domains to phosphorylated peptides. The BRCT domain and its capability to bind phosphorylated protein is required for the tumor suppressor function of BRCA1. Through its BRCT phospho-binding ability BRCA1 forms at least three mutually exclusive complexes by binding to phosphorylated proteins Abraxas, Bach1 and CTIP. The A, B and C complexes, at lease partially undertake BRCA1's role in mechanisms of cell cycle checkpoint and DNA repair that maintain genome stability, thus may play important roles in BRCA1's tumor suppressor function.

PMID:
22369660
[PubMed]
PMCID:
PMC3315748
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk